A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (NCT06499285)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
🩺 Plain-English Summary (8th-Grade Level)
The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (177 Sites)
Showing the first 25 of 177 sites.
- City of Hope — Duarte, California
- Los Angeles Cancer Network — Glendale, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Smilow Cancer Hospital at Yale-New Haven — New Haven, Connecticut
- University of Miami Hospital and Clinics — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
- ILCC. Illinois Cancer Centers — Peoria, Illinois
- Norton Cancer Institute — Louisville, Kentucky
- Maryland Oncology Hematolofy — Columbia, Maryland
- MidAmerica Cancer Care — Kansas City, Missouri
- Comprehensive Cancer Centers of Nevada — Henderson, Nevada
- Northwell Health — Lake Success, New York
- Clinical Research Alliance NY — Westbury, New York
- Novant Health-Cancer Institute — Winston-Salem, North Carolina
- Gabrail Cancer Center Research — Canton, Ohio
- Cleveland Clinic - Cleveland — Cleveland, Ohio
- Tennessee Cancer Specialists — Knoxville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- Texas Oncology Northeast Texas — Denison, Texas
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine — Houston, Texas
- Texas Oncology Gulf Coast — The Woodlands, Texas
- Tranquil Research — Webster, Texas
- The Canberra Hospital — Garran, Australian Capital Territory
- Westmead Hospital — Sydney, New South Wales
- Townsville University Hospital — Douglas, Queensland
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelodysplastic Syndromes
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions — Clovis, California
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA — Tampa, Florida
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) — Lakewood, California
- Inqovi Maintenance Therapy in Myeloid Neoplasms — Boston, Massachusetts
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) — Birmingham, Alabama
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome — Tampa, Florida
Explore by condition: All Myelodysplastic Syndromes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.